Skip to main content
. Author manuscript; available in PMC: 2017 Jun 5.
Published in final edited form as: Psychopharmacology (Berl). 2013 May 5;229(1):199–208. doi: 10.1007/s00213-013-3099-4

Table 3.

Self-Reported Anxiety after Each Experimental Phase by Treatment Group

Placebo
Oxytocin
Phase CS+ CS− CS+ CS−
Acquisitiona 5.55 (1.76) 2.35 (1.18) 6.5 (2.04) 2.39 (1.5)
Extinctionb 3.45 (2.01) 2 (1.17) 3.50 (2.62) 2.44 (1.89)
Recallb 1.8 (1.44) 2.75 (1.89) 3.94 (2.39) 2.11 (1.64)

Note. Standard deviations in parentheses.

a

indicates significant main effect of Cue within the acquisition phase (p < .05).

b

indicates a significant Cue x Phase interaction such that anxiety in response to the CS+ was significantly diminished relative to the acquisition phase, while there was no significant change in anxiety in response to the CS−. Scale: 1 = least anxious, 10 = most anxious.